Market Overview

UPDATE: Jefferies Raises PT on Eli Lilly & Co. as Least-Preferred Name

Share:
Related LLY
Attention To Details: Neos' ADHD Portfolio
Novartis Cardiovascular Drug Positive, NSCLC Drug Approved
Quick Tips on Investing in the Pharmaceutical and Medical Device Industry (GuruFocus)

In a report published Wednesday, Jefferies analyst Jeffrey Holford reiterated an Underperform rating on Eli Lilly & Co. (NYSE: LLY), and slightly raised the price target from $43.00 to $44.00.

In the report, Holford noted, “We remain positive on Pharmaceuticals and see valuation as attractive for most stocks. Our Top Pick in the US is AbbVie, with Novartis being our most preferred name in Europe. Sanofi, Roche and Pfizer remain high conviction Buy ratings. We point to Eli Lilly and GlaxoSmithKline as least preferred names.”

Eli Lilly & Co. closed on Tuesday at $56.74.

Latest Ratings for LLY

DateFirmActionFromTo
Apr 2017Argus ResearchDowngradesBuyHold
Apr 2017BMO CapitalDowngradesMarket PerformUnderperform
Apr 2017Morgan StanleyDowngradesOverweightEqual-Weight

View More Analyst Ratings for LLY
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings

 

Related Articles (LLY)

View Comments and Join the Discussion!